Jian-Ming Xu (Jianming Xu, J Xu, Jianmin Xu)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 15

Top Topics

Radiation Therapy

Circulating Tumor

Squamous Cell Carcinoma

Top Venues

Therapeutic advances in medical oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Shu-Kui Qin, Tian-Shu Liu, Jian-Ming Xu, Qi Li, Ying Cheng, Aimar Zhang, Regina Esser, Helena Chang, Jin Li
Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer. Future oncology (London, England) (2023)
Sicheng Du, Ying Zhang, Jian-Ming Xu
Current progress in cancer treatment by targeting FGFR signaling. Cancer biology & medicine 20 (7) (2023)
Jian-Ming Xu, Jiuwei Cui, Haiping Jiang, Yan Zeng, Xiuyu Cong
Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients. Cancer medicine (2023)
Shoujian Ji, Chuanhua Zhao, Rongrui Liu, Yan Wang, Qing Yang, Hua Yang, Jian-Ming Xu
A combined immune prognostic index in esophageal squamous cell carcinoma patients treated with anti-PD-1 therapy. Therapeutic advances in medical oncology 15 (2023)
Shu-Kui Qin, Jin Li, Yuxian Bai, Zishu Wang, Zhendong Chen, Rui-Hua Xu, Jian-Ming Xu, Hong-Mei Zhang, Jia Chen, Ying Yuan, Tianshu Liu, Lin Yang, Haijun Zhong, Donghui Chen, Lin Shen, Chunyi Hao, Deliang Fu, Ying Cheng, Jianwei Yang, Qiong Wang, Baoli Qin, Hongming Pan, Jun Zhang, Xianhong Bai, Qingshan Zheng
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Gehan Xu, Liang Cui, Jin Li, Quanren Wang, Pansong Li, Xuefeng Xia, Xin Yi, Quanlin Guan, Jian-Ming Xu
bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy. Clinical and translational medicine 12 (10) (2022)
Jian-Ming Xu, Yuxian Bai, Enxiao Li, Nong Xu, Danfeng Shi, Jing Qian
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review. Expert review of anticancer therapy 22 (9) (2022)
Jian-Ming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Lei Yang, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Yuxian Bai, Wei Li, Yiping Zhang, Guanghai Dai, Dong Ma, Jingdong Zhang, Chunmei Bai, Yunchao Huang, Wang-Jun Liao, Lin Wu, Xi Chen, Yan Yang, Junye Wang, Shoujian Ji, Hui Zhou, Yan Wang, Zhuo Ma, Yanqi Wang, Bo Peng, Jiya Sun, Christoph Mancao
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nature communications 13 (1) (2022)
Ru Jia, Yi Li, Nong Xu, Hai-Ping Jiang, Chuan-Hua Zhao, Rong-Rui Liu, Yue Shi, Yao-Yue Zhang, Shu-Yan Wang, Hui Zhou, Jian-Ming Xu
Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms. The oncologist 27 (8) (2022)
Zhaoli Tan, Chunyan Yue, Shoujian Ji, Chuanhua Zhao, Ru Jia, Yun Zhang, Rongrui Liu, Da Li, Qian Yu, Ping Li, Zhiyuan Hu, Yanlian Yang, Jian-Ming Xu
Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. The oncologist 26 (12) (2021)
S Ji, J Li, L Chang, C Zhao, R Jia, Z Tan, R Liu, Y Zhang, Y Li, G Yin, Y Guan, X Xia, X Yi, Jian-Ming Xu
Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 23 (8) (2021)
Jian-Ming Xu, Yuxian Bai, Hui-Chuan Sun, Chun-Mei Bai, Ru Jia, Yi Li, Wenjie Zhang, Lei Liu, Cheng Huang, Mei Guan, Jinghong Zhou, Weiguo Su
A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer 127 (21) (2021)
Rongrui Liu, Lianke Liu, Chuanhua Zhao, Yuxian Bai, Yulong Zheng, Shu Zhang, Ning Li, Jianwei Yang, Qingxia Fan, Xiuwen Wang, Shan Zeng, Yingjun Zhang, Weihong Zhang, Yulei Zhuang, Ning Kang, Yingzhi Jiang, Hongmei Sun, Jian-Ming Xu
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study. BMC gastroenterology 21 (1) (2021)
Yingcheng Wu, Shuaixi Yang, Jiaqiang Ma, Zechuan Chen, Guohe Song, Dongning Rao, Yifei Cheng, Siyuan Huang, Yifei Liu, Shan Jiang, Jinxia Liu, Xiaowu Huang, Xiaoying Wang, Shuangjian Qiu, Jian-Ming Xu, Ruibin Xi, Fan Bai, Jian Zhou, Jia Fan, Xiaoming Zhang, Qiang Gao
Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. Cancer discovery (2021)
Jian-Ming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequn Li, Xiaoming Chen, Zhiming Wang, Kangsheng Gu, Xi Chen, Zhanyu Pan, Kuansheng Ma, Xinmin Zhou, Zujiang Yu, Enxiao Li, Guowen Yin, Xiao Zhang, Shuni Wang, Quanren Wang
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (4) (2020)